Arie Nakhmani

Dr. Arie Nakhmani

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in Pattern Recognition Letters
Verified
Journal Article
Closed access
ANArie Nakhmani
Arie Nakhmani
ATAllen Tannenbaum
Allen Tannenbaum

1 January 2014 in Magnetic Resonance Imaging
Verified
Journal Article
Closed access
BBBrian Barry
Brian Barry
KBKaren Buch
Karen Buch
JSJorge A. Soto
Jorge A. Soto
HJHernan Jara
Hernan Jara
ANArie Nakhmani
Arie Nakhmani
SAStephan W. Anderson
Stephan W. Anderson

1 June 2023 in Radiology
Verified
Journal Article
Closed access
PPPraneeth Reddy Amudala Puchakayala
Praneeth Reddy Amudala Puchakayala
VSVenkata L. Sthanam
Venkata L. Sthanam
ANArie Nakhmani
Arie Nakhmani
MCMuhammad F. A. Chaudhary
Muhammad F. A. Chaudhary
APAbhilash Kizhakke Puliyakote
Abhilash Kizhakke Puliyakote
SBSandeep Bodduluri
Sandeep Bodduluri
Background Approximately half of adults with chronic obstructive pulmonary disease (COPD) remain undiagnosed. Chest CT scans are frequently acquired in clinical practice and present an opportunity to detect COPD. Purpose To assess the performance of radiomics features in COPD diagnosis using standard-dose and low-dose CT models. Materials and Methods This secondary analysis included participants enrolled in the Genetic Epidemiology of COPD, or COPDGene, study at baseline (visit 1) and 10 years after baseline (visit 3). COPD was defined by a forced expiratory volume in the 1st second of expiration to forced vital capacity ratio less than 0.70 at spirometry. The performance of demographics, CT emphysema percentage, radiomics features, and a combined feature set derived from inspiratory CT alone was evaluated. CatBoost (Yandex), a gradient boosting algorithm, was used to perform two classification experiments to detect COPD; the two models were trained and tested on standard-dose CT data from visit 1 (model I) and low-dose CT data from visit 3 (model II). Classification performance of the models was evaluated using area under the receiver operating characteristic curve (AUC) and precision-recall curve analysis. Results A total of 8878 participants (mean age, 57 years ± 9 [SD]; 4180 female, 4698 male) were evaluated. Radiomics features in model I achieved an AUC of 0.90 (95% CI: 0.88, 0.91) in the standard-dose CT test cohort versus demographics (AUC, 0.73; 95% CI: 0.71, 0.76; P < .001), emphysema percentage (AUC, 0.82; 95% CI 0.80, 0.84; P < .001), and combined features (AUC, 0.90; 95% CI: 0.89, 0.92; P = .16). Model II, trained on low-dose CT scans, achieved an AUC of 0.87 (95% CI: 0.83, 0.91) on the 20% held-out test set for radiomics features compared with demographics (AUC, 0.70; 95% CI: 0.64, 0.75; P = .001), emphysema percentage (AUC, 0.74; 95% CI: 0.69, 0.79; P = .002), and combined features (AUC, 0.88; 95% CI: 0.85, 0.92; P = .32). Density and texture features were the majority of the top 10 features in the standard-dose model, whereas shape features of lungs and airways were significant contributors in the low-dose CT model. Conclusion A combination of features representing parenchymal texture and lung and airway shape on inspiratory CT scans can be used to accurately detect COPD. ClinicalTrials.gov registration no. NCT00608764 © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Vliegenthart in this issue.

9 July 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
SBSandeep Bodduluri
Sandeep Bodduluri
ANArie Nakhmani
Arie Nakhmani
JRJoseph M. Reinhardt
Joseph M. Reinhardt
CWCarla G. Wilson
Carla G. Wilson
MMMerry-Lynn McDonald
Merry-Lynn McDonald
SBSurya Bhatt
Surya Bhatt
BACKGROUND: Currently recommended traditional spirometry outputs do not reflect the relative contributions of emphysema and airway disease to airflow obstruction. We hypothesized that machine-learning algorithms can be trained on spirometry data to identify these structural phenotypes. METHODS: Participants enrolled in a large multicenter study (COPDGene) were included. The data points from expiratory flow-volume curves were trained using a deep-learning model to predict structural phenotypes of chronic obstructive pulmonary disease (COPD) on CT, and results were compared with traditional spirometry metrics and an optimized random forest classifier. Area under the receiver operating characteristic curve (AUC) and weighted F-score were used to measure the discriminative accuracy of a fully convolutional neural network, random forest, and traditional spirometry metrics to phenotype CT as normal, emphysema-predominant (>5% emphysema), airway-predominant (Pi10 > median), and mixed phenotypes. Similar comparisons were made for the detection of functional small airway disease phenotype (>20% on parametric response mapping). RESULTS: Among 8980 individuals, the neural network was more accurate in discriminating predominant emphysema/airway phenotypes (AUC 0.80, 95%CI 0.79–0.81) compared with traditional measures of spirometry, FEV 1 /FVC (AUC 0.71, 95%CI 0.69–0.71), FEV 1 % predicted (AUC 0.70, 95%CI 0.68–0.71), and random forest classifier (AUC 0.78, 95%CI 0.77–0.79). The neural network was also more accurate in discriminating predominant emphysema/small airway phenotypes (AUC 0.91, 95%CI 0.90–0.92) compared with FEV 1 /FVC (AUC 0.80, 95%CI 0.78–0.82), FEV 1 % predicted (AUC 0.83, 95%CI 0.80–0.84), and with comparable accuracy with random forest classifier (AUC 0.90, 95%CI 0.88–0.91). CONCLUSIONS: Structural phenotypes of COPD can be identified from spirometry using deep-learning and machine-learning approaches, demonstrating their potential to identify individuals for targeted therapies. TRIAL REGISTRATION: ClinicalTrials.gov NCT00608764. FUNDING: This study was supported by NIH grants K23 HL133438 and R21EB027891 and an American Thoracic Foundation 2018 Unrestricted Research Grant. The COPDGene study is supported by NIH grants NHLBI U01 HL089897 and U01 HL089856. The COPDGene study (NCT00608764) is also supported by the COPD Foundation through contributions made to an Industry Advisory Committee comprising AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, and Sunovion.

1 December 2022 in Radiology
Verified
Journal Article
Closed access
SBSurya Bhatt
Surya Bhatt
SBSandeep Bodduluri
Sandeep Bodduluri
ANArie Nakhmani
Arie Nakhmani
YKYoung-Il Kim
Young-Il Kim
JRJoseph M. Reinhardt
Joseph M. Reinhardt
DDDawn L. DeMeo
Dawn L. DeMeo
In never-smokers, airway lumen at chest CT images was smaller in women than men; in ever-smokers, worsening of lumen size impacted respiratory outcomes more in women than men. Background The prevalence of chronic obstructive pulmonary disease (COPD) in women is fast approaching that in men, and women experience greater symptom burden. Although sex differences in emphysem...

30 November 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SBSurya Bhatt
Surya Bhatt
NBNirav R. Bhakta
Nirav R. Bhakta
CWCarla G. Wilson
Carla G. Wilson
CCChristopher B. Cooper
Christopher B. Cooper
IBIgor Barjaktarevic
Igor Barjaktarevic
ANArie Nakhmani
Arie Nakhmani
The diagnosis of chronic obstructive pulmonary disease (COPD) relies on demonstration of airflow obstruction. Traditional spirometric indices miss a number of subjects with respiratory symptoms or structural lung disease on imaging. We hypothesized that utilizing all data points on the expiratory spirometry curves to assess their shape will improve detection of mild airflow obstruction and structural lung disease. We analyzed spirometry data of 8307 participants enrolled in the COPDGene study, and derived metrics of airflow obstruction based on the shape on the volume-time (Parameter D), and flow-volume curves (Transition Point and Transition Distance). We tested associations of these parameters with CT measures of lung disease, respiratory morbidity, and mortality using regression analyses. There were significant correlations between FEV 1 /FVC with Parameter D (r = −0.83; p < 0.001), Transition Point (r = 0.69; p < 0.001), and Transition Distance (r = 0.50; p < 0.001). All metrics had significant associations with emphysema, small airway disease, dyspnea, and respiratory-quality of life (p < 0.001). The highest quartile for Parameter D was independently associated with all-cause mortality (adjusted HR 3.22,95% CI 2.42–4.27; p < 0.001) but a substantial number of participants in the highest quartile were categorized as GOLD 0 and 1 by traditional criteria (1.8% and 33.7%). Parameter D identified an additional 9.5% of participants with mild or non-recognized disease as abnormal with greater burden of structural lung disease compared with controls. The data points on the flow-volume and volume-time curves can be used to derive indices of airflow obstruction that identify additional subjects with disease who are deemed to be normal by traditional criteria.